• Logout
  • Profile
  • PortuguÍs
  • 0
    Category: Date -
    (e.g. ANVISA, AstraZeneca, insulin, S„o Paulo, public, drug pricing )
       BMS cuts HIV drug price in Peru after compulsory license threat  
    2015-07-14 - Bristol-Myers Squibb (BMS) is reported to have agreed to a 35% price reduction to its HIV drug Reyataz (atazanavir) in Peru, after protracted negotiations with the Ministry of Health (MoH). The price of the drug, an antiretroviral drug of the protease inhibitor (PI) class, has been cut from PEN 29.17 (price paid per tablet in 2013) to PEN 18.96 (USD 8.99 to USD 5.84), which will benefit Peru's population of 1,800 HIV/AIDS sufferers.

    Negotiations with BMS reportedly carried on for the past 12 months, and reportedly saw the MoH declare securing supplies of atazanavir as in the public interest, thereby making the drug eligible for compulsory licensing under World Trade Organization rules. The source notes that Reyataz's patent is valid until 2019 in Peru.
    Recent news    More>>
    Brazil's Fiocruz succeeds in technology transfer of GSK's triple vaccine 2019-03-14
    Roche's Hemcibra/Hemlibra lands usage extension in Brazil 2019-03-14
    Jazz Pharmaceuticalsí VOD drug Defitelio gets marketing nod in Brazil 2019-03-14
    Eli Lillyís Verzenios to compete for Brazil market with Pfizerís Ibrance 2019-03-14
    UFPR team searches for novel drugs in Brazilís biodiversity 2019-03-13
    Tecparís plasma treatment Tecplas gets new indication from Brazilís ANVISA 2019-03-13
    Brazilís ANVISA extends Prografís use to heart transplants 2019-03-12
    Related briefs   
    BMSís Opdivo gains indication for melanoma in Argentina 2019-01-04
    HCV patients pressure Colombiaís MoH for compulsory licenses 2018-11-07
    BMS's Opdivo-Yervoy combo therapy gains indication for kidney cancer in Brazil 2018-10-18
    Gilead maintains discount offer to Brazilís MoH on sofosbuvir alternatives 2018-09-25
    Brazil grants Gilead hepatitis C drug patent 2018-09-19
    Sanuwave and Tabarca form JV for devices across Latam 2018-06-27
    Aspen expands Mexican portfolio with Pentrexyl and Perfalga from MSD 2018-04-11
    Products mentioned:
    Companies mentioned:
    Bristol-Myers Squibb
    Policies mentioned:
      March 20, 2019 
             © 2019 GB Information. All Rights Reserved